Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Alliancebernstein L.P.

Alliancebernstein L.P. boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 326,802 shares of the medical equipment provider's stock after acquiring an additional 22,784 shares during the quarter. Alliancebernstein L.P. owned about 0.16% of Zimmer Biomet worth $34,520,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Zimmer Biomet during the fourth quarter worth about $216,223,000. Sound Shore Management Inc. CT purchased a new stake in Zimmer Biomet during the 4th quarter worth approximately $81,447,000. Equity Investment Corp lifted its holdings in Zimmer Biomet by 57.2% during the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider's stock worth $107,855,000 after buying an additional 371,653 shares in the last quarter. Van ECK Associates Corp boosted its position in Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after buying an additional 218,688 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Zimmer Biomet during the fourth quarter worth $21,234,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH traded down $3.12 on Thursday, reaching $100.32. The stock had a trading volume of 509,876 shares, compared to its average volume of 1,611,197. The firm has a 50-day moving average of $106.54 and a 200 day moving average of $107.10. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $19.97 billion, a PE ratio of 22.61, a PEG ratio of 1.95 and a beta of 0.84. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $128.55.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the company earned $2.20 EPS. Sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio is presently 21.57%.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. Raymond James lowered their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus boosted their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Barclays decreased their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Finally, Truist Financial reiterated a "hold" rating and issued a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $124.15.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.95% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.